Switzerland’s Ferring Pharmaceuticals has joined with US investor Blackstone Life Sciences to pump $570 million into a bladder cancer gene therapy project.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh